Clinical trial
Treatment of Relapsed Low-Grade or Follicular Lymphoma With Rituximab (Also…
NCT00168740 · Biogen, Industry · Completed
Key facts
| NCT number | NCT00168740 |
|---|---|
| Title | Treatment of Relapsed Low-Grade or Follicular Lymphoma With Rituximab (Also Known as Rituxan, IDEC-C2B8, IDEC-102) |
| Official title | Pivotal Phase III Multi-Center Study to Evaluate the Safety and Efficacy of Once Weekly Times Four Dosing of IDEC-C2B8 (IDEC-102) in Patients With Relapsed Low-Grade or Follicular B-Cell Lymphoma |
| Lead sponsor | Biogen, Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Low-Grade or Follicular B-Cell Non-Hodgkin's Lymphoma |
| Intervention type | Drug |
| Interventions | rituximab |
| Enrollment | 150 |
| Start date | Apr 1, 1995 |
| First posted | Sep 15, 2005 |
| Last update posted | Sep 15, 2005 |
| Countries | Canada, United States |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: